ArticleInternational journal of molecular sciences2026
CAFNet-DG: Task-Specific Modeling and Prevalence-Aware Evaluation for Adverse Drug Reaction Prioritization with Ordinal-Frequency Estimation.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Adverse drug reaction (ADR) prioritization and ordinal-frequency estimation are related but distinct prediction objectives, while aggregate ranking performance in sparse annotation matrices can be strongly influenced by frequently annotated side effects. Within CAFNet-DG, CAFNet-D uses task-specific association and ordinal-frequency functions built on shared molecular-relational representations, while annotation prevalence is evaluated explicitly within each training fold. On a SIDER-derived dataset comprising 750 drugs and 994 side effects, replacing a shared output with task-specific functions produced the largest joint change in staged drug-disjoint ablation, increasing mAP from 0.340 to 0.382 and reducing RMSE from 1.754 to 1.142. A prevalence-only ranking achieved an mAP of 0.410, close to the CAFNet-DG value of 0.413, indicating that aggregate ADR ranking is strongly associated with the benchmark annotation distribution. Prevalence-matched, prevalence-stratified, frequently annotated side-effect removal, and per-drug analyses were therefore used to distinguish drug-conditioned ranking variation from global annotation-prevalence effects. An equal-weight same-architecture ensemble control yielded no significant differences from CAFNet-DG across seven ranking metrics after Holm correction; generic variance reduction therefore could not be excluded as an explanation for the modest score-integration gain. Scaffold-disjoint and independent-data evaluations showed modest transfer, while ordinal-frequency agreement on CT-ADE remained limited. The results support the CAFNet-D task-specific formulation and prevalence-aware evaluation, while CAFNet-DG provides the score-integration setting examined under matched ensemble controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.